MB Therapeutics has raised $2.2M in seed funding to push forward its approach to personalized medicine. The round drew backing from Beprep, Calyseed, Angels Santé, Bpifrance, and Sébastien Gallice.
The company develops and produces personalized medicines using 3D printing, which allows it to customize dosage, shape, and active pharmaceutical ingredient within a GMP environment. That combination of flexibility and manufacturing compliance is the core of its pitch to patients and partners alike.
